0.05). PRT grubunun %100'ü EIIIB iken, RRT grubunun %63'ü EIIIA, %37'si EIIIB bulunmuştur (p=0.00000). Tedavi cevabı ve median sağ kalım, RRT grubunda anlamlı olarak yüksek çıkmıştır (%13 ve 11 aya karşı %3 ve 8 ay, p=0.00099 ve p=0.001). Ancak gruplar arasındaki bu sağ kalım farkının 3. yılda eşitlendiği gözlenmiştir. Sonuç olarak KPS>70 olan ve zorunlu palyasyonu gerekmeyen olgularımızda, RRT'nin uygun bir tedavi seçeneği olabileceği anlaşılmıştır. Our Inoperable Locally Advanced (Stage IIIA.B) Non-Small Cell Lung Cancer Patients: Results of Short-Term Low-Dose or Long-Term High-Dose Radiotherapy Administration. In this study, 71 patients with inoperable non-small cell lung cancer (INSCLC) given radiotherapy (RT) in our clinic from 1990 through 1995 were retrospectively analysed. In these patients who had not the requirement of immediate or obligatory palliation, selection of RT dose was prqspectively done only according to "Karnofsky Performance Score" (KPS): 33 patients who had KPS70 treated with high-dose radical (R) RT. In statistical analyses, there were no statistically significant difference and correlation between these two treatment groups according to age, sex and histological grade (p>0.05). While100% of patients in the PRT group was stage NIB, 63% of patients was stage IIIA and 37% was stage IIIB in the RRT group (p=0.00000). Treatment response and median survival were significantly higher in the RRT group than PRT group (13% and 11 months versus 3% and 8 months, p=0.00099 and p=0.001). However it was observed that the survival difference between these groups was come to the same level upto the 3rd year. . As a conclusion, it can be said that RRT may be a proper choice of treatment in patients with KPS>70 and who were not required an obligatory palliation. "> [PDF] İnopere, lokal ileri ( EIIIA-B ) küçük hücreli dışı akciğer kanseri olgularımız: Kısa süreli düşük doz veya uzun süreli yüksek doz radyoterapi uygulama sonuçları | [PDF] Our inoperable locally advanced ( Stage IIIA-B ) non-small cell lung cancer patients: Results of short-term low-dose or long-term high-dose radiotherapy administration 0.05). PRT grubunun %100'ü EIIIB iken, RRT grubunun %63'ü EIIIA, %37'si EIIIB bulunmuştur (p=0.00000). Tedavi cevabı ve median sağ kalım, RRT grubunda anlamlı olarak yüksek çıkmıştır (%13 ve 11 aya karşı %3 ve 8 ay, p=0.00099 ve p=0.001). Ancak gruplar arasındaki bu sağ kalım farkının 3. yılda eşitlendiği gözlenmiştir. Sonuç olarak KPS>70 olan ve zorunlu palyasyonu gerekmeyen olgularımızda, RRT'nin uygun bir tedavi seçeneği olabileceği anlaşılmıştır. "> 0.05). PRT grubunun %100'ü EIIIB iken, RRT grubunun %63'ü EIIIA, %37'si EIIIB bulunmuştur (p=0.00000). Tedavi cevabı ve median sağ kalım, RRT grubunda anlamlı olarak yüksek çıkmıştır (%13 ve 11 aya karşı %3 ve 8 ay, p=0.00099 ve p=0.001). Ancak gruplar arasındaki bu sağ kalım farkının 3. yılda eşitlendiği gözlenmiştir. Sonuç olarak KPS>70 olan ve zorunlu palyasyonu gerekmeyen olgularımızda, RRT'nin uygun bir tedavi seçeneği olabileceği anlaşılmıştır. Our Inoperable Locally Advanced (Stage IIIA.B) Non-Small Cell Lung Cancer Patients: Results of Short-Term Low-Dose or Long-Term High-Dose Radiotherapy Administration. In this study, 71 patients with inoperable non-small cell lung cancer (INSCLC) given radiotherapy (RT) in our clinic from 1990 through 1995 were retrospectively analysed. In these patients who had not the requirement of immediate or obligatory palliation, selection of RT dose was prqspectively done only according to "Karnofsky Performance Score" (KPS): 33 patients who had KPS70 treated with high-dose radical (R) RT. In statistical analyses, there were no statistically significant difference and correlation between these two treatment groups according to age, sex and histological grade (p>0.05). While100% of patients in the PRT group was stage NIB, 63% of patients was stage IIIA and 37% was stage IIIB in the RRT group (p=0.00000). Treatment response and median survival were significantly higher in the RRT group than PRT group (13% and 11 months versus 3% and 8 months, p=0.00099 and p=0.001). However it was observed that the survival difference between these groups was come to the same level upto the 3rd year. . As a conclusion, it can be said that RRT may be a proper choice of treatment in patients with KPS>70 and who were not required an obligatory palliation. ">
Erkut ERKURT, Fatma AKDOÄžAN, CandaÅŸ TUNALI

8392

İnopere, lokal ileri ( EIIIA-B ) küçük hücreli dışı akciğer kanseri olgularımız: Kısa süreli düşük doz veya uzun süreli yüksek doz radyoterapi uygulama sonuçları

Bu çalışmada, kliniğimizde, 1990-1995 yılları arasında eksternal radyoterapi (RT) verilen, 71 İnopere, lokal ileri, küçük hücreli dışı akciğer kanseri (KHDAK) olgusu retrospektif olarak incelenmiştir. Acil veya zorunlu palyasyon gerekmeyen bu olgularda, RT doz seçimi, prospektif olarak, sadece "Karnofsky Performance Score" (KPS)'una göre yapılmıştır: KPS70 olan 38'ine yüksek doz radikal (R) RT uygulanmıştır. İstatistik! analizlerde, iki tedavi grubu arasında yaş, cinsiyet, histolojik diferansiyasyon derecesine göre anlamlı fark ve korelasyon bulunamamıştır (p>0.05). PRT grubunun %100'ü EIIIB iken, RRT grubunun %63'ü EIIIA, %37'si EIIIB bulunmuştur (p=0.00000). Tedavi cevabı ve median sağ kalım, RRT grubunda anlamlı olarak yüksek çıkmıştır (%13 ve 11 aya karşı %3 ve 8 ay, p=0.00099 ve p=0.001). Ancak gruplar arasındaki bu sağ kalım farkının 3. yılda eşitlendiği gözlenmiştir. Sonuç olarak KPS>70 olan ve zorunlu palyasyonu gerekmeyen olgularımızda, RRT'nin uygun bir tedavi seçeneği olabileceği anlaşılmıştır.

Our inoperable locally advanced ( Stage IIIA-B ) non-small cell lung cancer patients: Results of short-term low-dose or long-term high-dose radiotherapy administration

Our Inoperable Locally Advanced (Stage IIIA.B) Non-Small Cell Lung Cancer Patients: Results of Short-Term Low-Dose or Long-Term High-Dose Radiotherapy Administration. In this study, 71 patients with inoperable non-small cell lung cancer (INSCLC) given radiotherapy (RT) in our clinic from 1990 through 1995 were retrospectively analysed. In these patients who had not the requirement of immediate or obligatory palliation, selection of RT dose was prqspectively done only according to "Karnofsky Performance Score" (KPS): 33 patients who had KPS70 treated with high-dose radical (R) RT. In statistical analyses, there were no statistically significant difference and correlation between these two treatment groups according to age, sex and histological grade (p>0.05). While100% of patients in the PRT group was stage NIB, 63% of patients was stage IIIA and 37% was stage IIIB in the RRT group (p=0.00000). Treatment response and median survival were significantly higher in the RRT group than PRT group (13% and 11 months versus 3% and 8 months, p=0.00099 and p=0.001). However it was observed that the survival difference between these groups was come to the same level upto the 3rd year. . As a conclusion, it can be said that RRT may be a proper choice of treatment in patients with KPS>70 and who were not required an obligatory palliation.
PDF

___

  • 1. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or single fraction in patients with inoperable non-small cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer 1992; 65:6, 934-41.
  • 2. Ampil FL, Sanghani SV: Timing of radiotherapy in asymptomatic patients with inoperable non-small cell lung cancer: a survival analysis and literature review. Radiat Med 1996; 14:4, 211-4.
  • 3. Andrea B, Payne D : Radiotherapy in the management of non-small-cell lung cancer. World J Surg 1993; 17, 741-750.
  • 4. Ball D, Matyhews J, Worotniuk V, et al: Longer survival with higher doses of thoracic radiotherapy in patients with limited non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 25, 599-604.
  • 5. Beahrs OH, Hemon DH, Hutter RVP: Staging of Cancer American Joint Committe on Cancer, 4 th ed. Philadelphia, JB Lippincott Co., 1993.
  • 6. Bleehen NM, Cox JR: Radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 1985; 11, 1001-1007.
  • 7. Byhardt RW: The evolution of Radiation Therapy Oncology Group (RTOG) Protocols for nonsmall cell lung cancer. Int J Radiat oncol biol phys 1995; 32:5, 1513-1525.
  • 8. Cox JD, Azarnia N, Byhardt RW, et al: N2 (clinical) nonsmall cell carcinoma of the lung: Prospective trials with total doses 60Gy by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991; 20, 7-12.
  • 9. Dillman OR, Seagren SL, Propert KJ, et al: A Randomized Trial Of Induction Chemotherapy Plus High-Dose Radiation Versus Radiation Alone In Stage III Non-Small-Cell Lung Cancer. N Engl J Med 1990; 323, 940-5.
  • 10. Doseretz DE, Katin MJ, Blitzer PH, et al: Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys 1992; 24, 3-9.
  • 11. Hayakawa A, Mitsuhashi N, Fruta M, et al: High dose radiation therapy for inoperable non-small cell lung cancer without mediastinal involvement (clinical stage N0, N1). Strahlenther Onkol 1996; 172:9, 489-95.
  • 12. Koukourakis M, Skarlatos J, Kosmo L, et al: Radiotherapy alone for non-small cell lung carcinoma. Five-year disease-free survival and patterns of failure. Acta Oncol 1995; 34:4, 525-30.
  • 13. Livingston RB: Current Management of Unresectable Non-Small Cell Lung Cancer. Seminars in Oncology 1994; 21:5 (Suppl 10), 4-13.
  • 14. Macbeth FR, Bolger JJ, Hopwood P, et al: Randomized trial of palliative two-fraction versus more intensive 13 fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 1996; 8:3, 167-75.
  • 15. Payne DG: Non-small-cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy ? J Clin Oncol 1988; 6, 552-8.
  • 16. Perez C A, Bauer M, Edelstein S, et al: Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12, 539-547.
  • 17. Perez CA, Pajak TF, Rubin P, et al: Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 1987; 59, 1874-81.
  • 18. Perez CA, Stanley K, Rubin P, et al: A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Cancer 1980; 45, 2744-2753.
  • 19. Reinfuss M, Skolyzewski J, Kowalska T, et al: Palliative radiotherapy in asymptomatic patients with locally advanced, unresectable, non-small cell lung cancer. Strahlenther Onkol 1993; 169:12, 709- 15.
  • 20. Ruckdeschel JC, Wagner H, Robinson LA. Locally Advanced Lung Cancer: Controversies In Management in ASCO Educational Book. 32nd Annual Meeting May 18-21, 1996 Philadelphia, Pennsylvania, p 220-228.
  • 21. Sause W, Scott C, Byhardt RW, et al.: Recursive partitioning analysis of 1592 patients on four RTOG studies in nonsmall cell lung cancer. J Clin Oncol 1993; 12, 336(1123).
  • 22. Stanley KE: Prognostic Factors for Survival in Patients With Inoperable Lung Cancer. JNCI 1980; 65, 25-32.
  • 23. Trovo MG, Minatel E, Franchin G, et al: Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24:1, 11-5.
  • 24. Wurschmidt F, Bunemann H, Bunemann C, et al: Inoperable non-small cell lung cancer: A retrospective analysis of 427 patients treated with high-dose radiotherapy. Int J Radiat Oncol Biol Phys 1994; 28:3, 583-8.
Çukurova Üniversitesi Tıp Fakültesi Dergisi-Cover
  • ISSN: 0250-5150
  • Yayın Aralığı: 4
  • Yayıncı: Tülay Candan
ArÅŸiv
Sayıdaki Diğer Makaleler

Panik bozukluğu sağaltımında bilişsel-davranışçı terapi ve farmakoterapi: Bir olgu

Rasim Somer DİLER, Nurgül ÖZPOYRAZ, Lut TAMAM

Propofol enjeksiyon ağrısına alfentanil ve lidokainin etkisi

Mustafa KARAKAN, Nursan TAHTACI, Ünsal ÖNER

Nwts-3 protokolü ile tedavi edilen wilms' tümörlü olguların değerlendirilmesi

Erkut ERKURT, Recep TUNCER, Nurdan TUNALI, Atila TANYELİ, İlgen ŞAŞMAZ, Candaş TUNALI, Suat ARSLANBAŞ, Bülent ANTMEN

Karaciğer sirozu ile birlikte seyreden Niemann-Pick hastalığı tip B olgusu

Erhun KASIRGA, Mahmut ÇOKER, Halil NARİN, A. Rahmi BAKİLER, Gül YÜCE

Parotis bezinde gerçek malign mikst tümör

A. Cemal AYGIT, Selçuk BİLGİ, Akın DEMİRALAY, M. Semih AYHAN

İnopere, lokal ileri ( EIIIA-B ) küçük hücreli dışı akciğer kanseri olgularımız: Kısa süreli düşük doz veya uzun süreli yüksek doz radyoterapi uygulama sonuçları

Erkut ERKURT, Fatma AKDOÄžAN, CandaÅŸ TUNALI

Benzer psikopatolojik özellikler gösteren, konversiyon bozukluğu ve kısa psikotik bozukluk tanilarıyla izlenen iki olgunun sunumu

Rasim Somer DİLER, Nurgül ÖZPOYRAZ, Şükrü UĞUZ, Lut TAMAM

Aynı hastanın kaptoprilli renografisinde iki farklı sonuç

Gülgün BÜYÜKDERELİ, Saime PAYDAŞ, Özoğul SARGIN

Familyal nörofibromatosisli bir olguda hipertrofik kardiyomiyopati

İbrahim Halil KURT, Ayhan USAL, Hasan KAVUKÇU

Kocaeli' nde çalışan bir grup hekimde evlilik doyumu

Mehmet ÃœNAL, S. Halime ASLAN, R. OÄŸuz ASLAN, Z. Nazan ALPARSLAN